Market capitalization | $13.67b |
Enterprise Value | $13.23b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 10.95 |
P/S ratio (TTM) P/S ratio | 11.31 |
P/B ratio (TTM) P/B ratio | 17.14 |
Sales growth (TTM) Sales growth | 39.26% |
Turnover (TTM) Turnover | $1.21b |
As a free StocksGuide basic user, you can view the scores for all 6,951 shares worldwide.
19 Analysts have issued a Natera, Inc. forecast:
19 Analysts have issued a Natera, Inc. forecast:
Mar '24 |
+/-
%
|
||
Turnover | 1,209 1,209 |
39%
39%
|
|
Gross income | 608 608 |
66%
66%
|
|
EBITDA | -342 -342 |
33%
33%
|
EBIT (operating result) EBIT | -382 -382 |
30%
30%
|
Net profit | -365 -365 |
33%
33%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.
Head office | United States |
CEO | Stephen Chapman |
Employees | 3,293 |
Founded | 2004 |
Website | www.natera.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.